OncLive’s Post

Want to learn more about the TROPION-Lung01 trial? Dana-Farber Cancer Institute's Dr. Jacob Sands dives into the data on OncLive, comparing the results of datopotamab deruxtecan versus docetaxel in non-squamous non-small cell lung cancer. Great overview! Check out the video. #lungcancer #cancer #oncology https://lnkd.in/e85tyyZe

Circulating tumor DNA (ctDNA) can detect primary resistance to immunotherapy in patients with lung cancer. In the first stage of this phase 2 trial, we evaluated 50 patients with advanced non-small cell lung cancer who received standard of care pembrolizumab to determine ctDNA response and its concordance with imaging. The primary endpoint was achieved and showed an impressive 82% sensitivity and 75% specificity in predicting radiologic response. These findings are guiding the ctDNA driven second stage of this trial where patients at risk of early progression are randomized to treatment intensification. Check out this one-page graphical summary of the manuscript.

Circulating tumor DNA (ctDNA) can detect primary resistance to immunotherapy in patients with lung cancer. In the first stage of this phase 2 trial, we evaluated 50 patients with advanced non-small cell lung cancer who received standard of care pembrolizumab to determine ctDNA response and its concordance with imaging. The primary endpoint was achieved and showed an impressive 82% sensitivity and 75% specificity in predicting radiologic response. These findings are guiding the ctDNA driven second stage of this trial where patients at risk of early progression are randomized to treatment intensification. Check out this one-page graphical summary of the manuscript.

Circulating tumor DNA (ctDNA) can detect primary resistance to immunotherapy in patients with lung cancer. In the first stage of this phase 2 trial, we evaluated 50 patients with advanced non-small cell lung cancer who received standard of care pembrolizumab to determine ctDNA response and its concordance with imaging. The primary endpoint was achieved and showed an impressive 82% sensitivity and 75% specificity in predicting radiologic response. These findings are guiding the ctDNA driven second stage of this trial where patients at risk of early progression are randomized to treatment intensification. Check out this one-page graphical summary of the manuscript.

Circulating tumor DNA (ctDNA) can detect primary resistance to immunotherapy in patients with lung cancer. In the first stage of this phase 2 trial, we evaluated 50 patients with advanced non-small cell lung cancer who received standard of care pembrolizumab to determine ctDNA response and its concordance with imaging. The primary endpoint was achieved and showed an impressive 82% sensitivity and 75% specificity in predicting radiologic response. These findings are guiding the ctDNA driven second stage of this trial where patients at risk of early progression are randomized to treatment intensification. Check out this one-page graphical summary of the manuscript.

Circulating tumor DNA (ctDNA) can detect primary resistance to immunotherapy in patients with lung cancer. In the first stage of this phase 2 trial, we evaluated 50 patients with advanced non-small cell lung cancer who received standard of care pembrolizumab to determine ctDNA response and its concordance with imaging. The primary endpoint was achieved and showed an impressive 82% sensitivity and 75% specificity in predicting radiologic response. These findings are guiding the ctDNA driven second stage of this trial where patients at risk of early progression are randomized to treatment intensification. Check out this one-page graphical summary of the manuscript.

Circulating tumor DNA (ctDNA) can detect primary resistance to immunotherapy in patients with lung cancer. In the first stage of this phase 2 trial, we evaluated 50 patients with advanced non-small cell lung cancer who received standard of care pembrolizumab to determine ctDNA response and its concordance with imaging. The primary endpoint was achieved and showed an impressive 82% sensitivity and 75% specificity in predicting radiologic response. These findings are guiding the ctDNA driven second stage of this trial where patients at risk of early progression are randomized to treatment intensification. Check out this one-page graphical summary of the manuscript.

Circulating tumor DNA (ctDNA) can detect primary resistance to immunotherapy in patients with lung cancer. In the first stage of this phase 2 trial, we evaluated 50 patients with advanced non-small cell lung cancer who received standard of care pembrolizumab to determine ctDNA response and its concordance with imaging. The primary endpoint was achieved and showed an impressive 82% sensitivity and 75% specificity in predicting radiologic response. These findings are guiding the ctDNA driven second stage of this trial where patients at risk of early progression are randomized to treatment intensification. Check out this one-page graphical summary of the manuscript.

The proto-oncogene tyrosine-protein kinase-1 (Ros-1)-gene fusion is expressed in non-small cell lung cancer (NSCLC). The ROS1 Zeta-Antibody clone ZR400 readily assesses the ROS1 antigen as well as ROS1-fusion variants in lung cancer tissue.

Building on its successful strategy in MM, Johnson & Johnson is tackling solid tumors with a similar approach of combining therapeutic mechanisms. The pharma to present trio of studies on bispecific Rybrevant in lung cancer at #ESMO23